Fatty Liver (NAFLD/NASH) Clinical Trial
Are there any FDA approved drugs for NASH?
Nonalcoholic steatohepatitis (NASH) is a subcategory of nonalcoholic fatty liver disease (NAFLD). NASH carries a significant disease burden as it can progress to cirrhosis and liver failure and is associated with an increase incidence of liver cancer. Currently, the U.S. Food and Drug Administration (FDA) has not approved any therapies for NASH.
Currently weight loss is the recommended management for NAFLD/NASH.
None of the drugs have been approved by the Food and Drug Administration for treating biopsy-proven non-alcoholic steatohepatitis (NASH).
What are clinical trials for NAFLD?
Clinical trials—and other types of clinical studies NIH external link —are part of medical research and involve people like you. When you volunteer to take part in a clinical study, you help doctors and researchers learn more about disease and improve health care for people in the future.
Researchers are studying many aspects of nonalcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH). For example, researchers are studying
new treatments for NASH
how genes may increase the risk for NAFLD
how liver diseases, such as NAFLD, develop and progress over time